Despite his historic wariness of the pharmaceutical industry, Robert F. Kennedy Jr.’s stance toward weight-loss drugs appears to be softening.
In December 2024, President Donald Trump’s nominee to lead the Department of Health and Human Services asserted that GLP-1 medications such as Ozempic and Mounjaro “have a place” in treating obesity. In his recent Senate confirmation hearings, Kennedy touted the effectiveness of GLP-1s, calling them “miracle drugs.” He’s right — just ask George Barlow.
Recommended Stories
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.